Related Experiment Video

Updated: May 26, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Statin-induced low cholesterol is not associated with poor outcome in chronic heart failure

Sérgio Silva1, Patrícia Lourenço, Cristiana Paulo

  • 1Serviço de Medicina Interna Hospital São João, Faculdade de Medicina da Universidade do Porto, Unidade I&D Cardiovascular do Porto, Porto, Portugal. sergiomiguelas@gmail.com

Journal of Cardiovascular Pharmacology and Therapeutics
|December 17, 2011
PubMed

Insights

Patients with heart failure (HF) and intrinsically low cholesterol face double the death risk compared to those with statin-induced low cholesterol. Statins may offer a survival benefit in HF patients, regardless of baseline cholesterol levels.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Research

Background:

  • Low cholesterol levels are linked to poorer outcomes in heart failure (HF) patients.
  • The role of statins in HF management remains a subject of debate.
  • This study differentiates prognosis based on the cause of low cholesterol.

Purpose of the Study:

  • To investigate if the prognosis of HF patients with intrinsically low cholesterol differs from those with statin-induced low cholesterol.
  • To evaluate the impact of statin therapy on mortality in HF patients with varying cholesterol levels.

Main Methods:

  • A retrospective cohort study of 464 ambulatory HF patients.
  • Patients were categorized into four groups based on statin use and cholesterol levels (<150 mg/dL vs. ≥150 mg/dL).
  • All-cause mortality was assessed over a 5-year follow-up period using Cox regression analysis.

Main Results:

  • Patients with intrinsically low cholesterol had a 5-year all-cause death hazard ratio of 2.38 (1.08-7.14) compared to those with statin-induced low cholesterol.
  • This association remained significant and independent of other prognostic factors.
  • The study included a diverse HF population, with 22.8% having preserved ejection fraction and 43.5% severe systolic dysfunction.

Conclusions:

  • Intrinsically low cholesterol levels in HF patients are associated with a significantly higher risk of mortality.
  • Pharmacologically induced low cholesterol through statin use does not appear to confer the same adverse prognosis.
  • Clinicians should consider the benefits of statins in HF patients, even those with low cholesterol, rather than withholding treatment due to fear of lowering cholesterol levels.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...